E Fund Management Co., Ltd. Mirati Therapeutics, Inc. Transaction History

E Fund Management Co., Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$41.99 - $62.38 $181,396 - $269,481	-4,320 Reduced 33.69%	8,503 $499,000
Q3 2023 Nov 13, 2023	BUY	$27.8 - $45.35 $29,551 - $48,207	1,063 Added 9.04%	12,823 $559,000
Q2 2023 Aug 11, 2023	BUY	$36.13 - $49.49 $69,116 - $94,674	1,913 Added 19.43%	11,760 $425,000
Q1 2023 May 11, 2023	SELL	$36.54 - $54.26 $7,600 - $11,286	-208 Reduced 2.07%	9,847 $366,000
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $183,032 - $437,379	4,435 Added 78.91%	10,055 $456,000
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $106,683 - $155,453	-1,793 Reduced 24.19%	5,620 $393,000
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $160,242 - $363,001	4,092 Added 123.22%	7,413 $498,000
Q1 2022 May 12, 2022	BUY	$75.82 - $150.97 $196,525 - $391,314	2,592 Added 355.56%	3,321 $273,000
Q1 2021 May 12, 2021	BUY	$158.92 - $221.61 $115,852 - $161,553	729 New	729 $124,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.